Tenax Therapeutics (NASDAQ:TENX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Tenax Therapeutics (NASDAQ:TENX) in a report issued on Thursday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.

Tenax Therapeutics Trading Up 1.2 %

Shares of NASDAQ:TENX opened at $3.49 on Thursday. The business’s 50 day simple moving average is $3.73 and its two-hundred day simple moving average is $3.61. Tenax Therapeutics has a 52-week low of $2.77 and a 52-week high of $61.20.

Tenax Therapeutics (NASDAQ:TENX) last announced its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.99) by $0.16. On average, research analysts expect that Tenax Therapeutics will post -6.68 earnings per share for the current fiscal year.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.